ARB类药物的不同治疗选择。该选用哪一种？何时使用？为何这样用？
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?
作者信息
Dézsi Csaba András
机构信息
Department of Cardiology, Petz Aladár County Teaching Hospital, Gyor, Hungary.
出版信息
Am J Cardiovasc Drugs. 2016 Aug;16(4):255-266. doi: 10.1007/s40256-016-0165-4.
Abstract
The renin-angiotensin-aldosterone system plays an important role in the pathophysiology of hypertension and is closely related with cardio- and cerebrovascular events and chronic kidney diseases. Each angiotensin receptor blocker (ARB) is important in the treatment of hypertension, according to the results of recent years. This is a practical review of the available evidence on the different benefits of ARBs beyond their blood pressure-lowering effect, with an emphasis on the differences found between the particular compounds and the therapeutic implications of the findings, with specific reference to the co-morbidities.
摘要
肾素-血管紧张素-醛固酮系统在高血压的病理生理学中起重要作用，并且与心脑血管事件及慢性肾脏疾病密切相关。根据近年来的研究结果，每种血管紧张素受体阻滞剂（ARB）在高血压治疗中都很重要。本文对ARB除降压作用外的不同益处的现有证据进行了实用综述，重点阐述了特定化合物之间的差异以及这些发现的治疗意义，并特别提及了合并症。
相似文献
1
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?ARB类药物的不同治疗选择。该选用哪一种？何时使用？为何这样用？
Am J Cardiovasc Drugs. 2016 Aug;16(4):255-266. doi: 10.1007/s40256-016-0165-4.
2
Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.超越血压：肾素-血管紧张素系统阻滞剂对心血管、脑血管及肾脏的保护作用证据
Ther Adv Cardiovasc Dis. 2012 Apr;6(2):81-91. doi: 10.1177/1753944712444866. Epub 2012 Apr 23.
3
Recent changes in the landscape of combination RAS blockade.联合RAS阻断领域的近期变化。
Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127.
4
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.双重阻断肾素-血管紧张素-醛固酮系统：超越 ACEI 与血管紧张素 II 受体阻滞剂的联合。
Am J Hypertens. 2009 Oct;22(10):1032-40. doi: 10.1038/ajh.2009.138. Epub 2009 Aug 6.
5
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?在 5/6 肾切除 Ren-2 转基因大鼠中，血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂依赖和不依赖肾素-血管紧张素系统的降压治疗对肾脏的保护作用相似：是否存在血压独立的作用？
Clin Exp Pharmacol Physiol. 2010 Dec;37(12):1159-69. doi: 10.1111/j.1440-1681.2010.05453.x.
6
Angiotensin II-receptor antagonist in the treatment of hypertension.血管紧张素II受体拮抗剂在高血压治疗中的应用
Curr Hypertens Rep. 2005 Aug;7(4):287-93. doi: 10.1007/s11906-005-0027-y.
7
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用：我们能否做得更好？
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
8
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.用于治疗高血压及相关疾病的新型肾素-血管紧张素-醛固酮系统阻断疗法。
J Hypertens. 2007 Jan;25(1):25-35. doi: 10.1097/HJH.0b013e3280113950.
9
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.血管、心脏、代谢和肾脏疾病动物模型中的血管紧张素 II 型 1 受体拮抗剂。
Pharmacol Ther. 2016 Aug;164:1-81. doi: 10.1016/j.pharmthera.2016.03.019. Epub 2016 Apr 27.
10
Renin-angiotensin system blocking drugs.肾素-血管紧张素系统阻断药物
J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):14-33. doi: 10.1177/1074248413501018. Epub 2013 Sep 13.
引用本文的文献
1
Comparative Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers in Hypertensive Patients With Chronic Kidney Disease: A Systematic Review.血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和钙通道阻滞剂在慢性肾病高血压患者中的疗效和安全性比较：一项系统评价
Cureus. 2025 Feb 11;17(2):e78845. doi: 10.7759/cureus.78845. eCollection 2025 Feb.
2
Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.肾素-血管紧张素系统抑制剂对转移性非小细胞肺癌患者生存率的影响。
Ann Saudi Med. 2025 Jan-Feb;45(1):18-24. doi: 10.5144/0256-4947.2025.18. Epub 2025 Feb 6.
3
A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies.心血管疾病管理的综合述评：心脏生物标志物、成像方式、药物治疗、手术干预和草药疗法。
Cells. 2024 Sep 1;13(17):1471. doi: 10.3390/cells13171471.
4
Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study.比较替米沙坦+比索洛尔复方制剂与替米沙坦+琥珀酸美托洛尔缓释片联合治疗 1 级和 2 级高血压的疗效、安全性和耐受性：一项双盲、多中心、III 期临床研究。
Indian Heart J. 2024 May-Jun;76(3):159-166. doi: 10.1016/j.ihj.2024.06.002. Epub 2024 Jun 12.
5
Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis.血管紧张素受体阻滞剂降低夜间血压的疗效：系统评价和荟萃分析。
Ann Med. 2024 Dec;56(1):2362880. doi: 10.1080/07853890.2024.2362880. Epub 2024 Jun 3.
6
Renin and renin blockade have no role in complement activity.肾素和肾素阻断在补体活性中不起作用。
Kidney Int. 2024 Feb;105(2):328-337. doi: 10.1016/j.kint.2023.11.005. Epub 2023 Nov 25.
7
Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.药用（放射性）化学：为未来构建放射性药物。
Curr Med Chem. 2024;31(34):5481-5534. doi: 10.2174/0929867331666230818092634.
8
Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.三联血管内皮生长因子受体（VEGFR）抑制剂替沃扎尼在小鼠模型中诱发高血压的潜在机制
Pharmaceuticals (Basel). 2023 Feb 14;16(2):295. doi: 10.3390/ph16020295.
9
RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus.印度糖尿病学会（RSSDI）糖尿病患者高血压管理指南
Int J Diabetes Dev Ctries. 2022 Oct;42(4):576-605. doi: 10.1007/s13410-022-01143-7. Epub 2022 Dec 15.
10
Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans.基于人群的发现和孟德尔随机化分析将替米沙坦鉴定为非裔美国人阿尔茨海默病的候选药物。
Alzheimers Dement. 2023 May;19(5):1876-1887. doi: 10.1002/alz.12819. Epub 2022 Nov 4.
本文引用的文献
1
The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics.非马沙坦治疗心血管事件和代谢综合征的疗效（K-MetS研究）：原理、设计与参与者特征
Pulse (Basel). 2014 May;1(3-4):177-85. doi: 10.1159/000360965. Epub 2014 Apr 23.
2
3
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.降压药物在糖尿病合并肾脏疾病成人患者中的疗效与安全性比较：网状荟萃分析。
Lancet. 2015 May 23;385(9982):2047-56. doi: 10.1016/S0140-6736(14)62459-4.
4
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.冠状动脉疾病患者的高血压治疗：美国心脏协会、美国心脏病学会和美国高血压学会的科学声明
J Am Soc Hypertens. 2015 Jun;9(6):453-98. doi: 10.1016/j.jash.2015.03.002. Epub 2015 Mar 31.
5
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker.氯沙坦对病态窦房结综合征患者预防阵发性心房颤动的有益作用：基于起搏器记忆功能的分析
Heart Vessels. 2016 Mar;31(3):402-7. doi: 10.1007/s00380-015-0627-7. Epub 2015 Mar 19.
6
Initial reduction of oxidative stress by angiotensin receptor blocker contributes long term outcomes after percutaneous coronary intervention.血管紧张素受体阻滞剂对氧化应激的初始降低作用有助于经皮冠状动脉介入治疗后的长期预后。
Am J Cardiovasc Dis. 2014 Dec 29;4(4):159-67. eCollection 2014.
7
Diagnosis, treatment, and prevention of gout.痛风的诊断、治疗与预防。
Am Fam Physician. 2014 Dec 15;90(12):831-6.
8
Effect of an angiotensin II receptor blocker and a calcium channel blocker on hypertension associated penile dysfunction in a rat model.血管紧张素II受体阻滞剂和钙通道阻滞剂对大鼠模型中高血压相关性阴茎功能障碍的影响。
Biomed Res. 2014;35(3):215-21. doi: 10.2220/biomedres.35.215.
9
Telmisartan attenuates cognitive impairment caused by chronic stress in rats.替米沙坦可减轻大鼠慢性应激所致的认知障碍。
Pharmacol Rep. 2014 Jun;66(3):436-41. doi: 10.1016/j.pharep.2013.11.002. Epub 2014 Apr 2.
10
Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.不同血管紧张素受体阻滞剂与糖尿病发病率：一项基于全国人群的队列研究。
Cardiovasc Diabetol. 2014 May 14;13:91. doi: 10.1186/1475-2840-13-91.
Zotero 插件